Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Adverse drug reactions

Increased risk of severe skin reactions with expectorants containing ambroxol or bromhexine

Patients taking expectorants containing ambroxol or bromhexine have a small increased risk of severe skin reactions such as Stevens-Johnson syndrome or erythema multiforme, says the European Medicine Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) following a safety review.

The expectorants, available over the counter and widely used outside the UK, are traditionally given to thin the mucus of patients with lung disease.

The PRAC has recommended that a new side effect warning is added to product information.

The review was prompted by original concerns raised by Belgium’s medicines safety regulator following reports of allergic reactions and severe skin reactions with ambroxol. The review was extended to include bromhexine-containing products as bromhexine can be converted into ambroxol in the body.

The revised product information, which includes a general warning about the small possibility of a severe allergic reaction, will also apply to lozenges containing ambroxol for treating sore throats.

The new warnings will also appear in information for ambroxol formulations offered via injection to prevent and treat lung complications post-surgery, as well as to treat respiratory distress syndrome in premature or newborn babies or to increase lung development after birth.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067567

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.